Drugs / IFN peg alfa-2b
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01010646 Comparator | Mar 2010 → Sep 2012 | chronic hepatitis C virus infection | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IFN peg alfa-2b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01010646 ↗ |
| Route | Subcutaneous | “IFN peg alfa-2b 1.5 µg/kg,administered once a week for 12 weeks by subcutaneous injections” NCT01010646 ↗ |